Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases globally. Its product portfolio includes DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify areas of reduced blood flow in the brain due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the heart muscle; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent for imaging PSMA-positive lesions in men with prostate cancer. The company also offers Automated Bone Scan Index, which uses an artificial neural network to calculate prostate cancer disease burden from bone scans, and aPROMISE and PYLARIFY AI, artificial intelligence medical device software for quantitative assessment of PSMA PET/CT images. Additionally, Lantheus develops therapeutic candidates such as PNT2002 for metastatic castration-resistant prostate cancer and PNT2003 for SSTR-positive neuroendocrine tumors.

Lantheus Holdings, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol LNTH. The company operates in the United States and its financials are reported in US Dollars (USD). As a US-based company trading on a major US exchange, its stock is traded in USD, making it accessible to investors through standard US brokerage accounts.

Lantheus Holdings, Inc. operates in the Healthcare sector and is classified under the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the development and production of specialized pharmaceutical products, including both diagnostic imaging agents and therapeutic radiopharmaceuticals. Unlike large-cap pharmaceutical companies that focus on blockbuster drugs, Lantheus specializes in niche areas such as nuclear medicine, ultrasound enhancing agents, and targeted therapies for cancer and other diseases.

Lantheus Holdings, Inc. is headquartered in the United States and serves a global market. The company's products are used by clinicians worldwide for the diagnosis and treatment of heart disease, cancer, and other conditions. While the company is based in the US, its radiopharmaceuticals and diagnostic agents are distributed internationally, supporting healthcare providers in various regions. The company's global reach is evident in its product portfolio, which includes imaging agents like PYLARIFY for prostate cancer and therapeutic candidates such as PNT2002 and PNT2003, targeting patients with metastatic castration-resistant prostate cancer and neuroendocrine tumors, respectively.

Lantheus Holdings has a diverse portfolio of diagnostic and therapeutic products. Key diagnostic products include DEFINITY, an injectable ultrasound enhancing agent for echocardiography; TechneLite, a technetium generator for nuclear medicine; Xenon-133, a radiopharmaceutical gas for pulmonary function assessment; Neurolite, an imaging agent for stroke evaluation; Cardiolite, a Tc-99m-labeled agent for cardiac blood flow assessment; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent for prostate cancer imaging. The company also offers software solutions like Automated Bone Scan Index, aPROMISE, and PYLARIFY AI, which use artificial intelligence to analyze medical images. In the therapeutic pipeline, Lantheus is developing PNT2002 for metastatic castration-resistant prostate cancer and PNT2003 for SSTR-positive neuroendocrine tumors. Additionally, the company markets RELISTOR for opioid-induced constipation and flurpiridaz for assessing blood flow to the heart.